OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
25
Results
Show all
Save search
Copy query
Show results for
Unknown
(25)
Publication Date
Release Date
2023
(6)
2025
(5)
2021
(4)
2024
(3)
2022
(3)
2026
(1)
2019
(1)
2017
(1)
2015
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
The role of neuromedin U in adiposity regulation. Haplotype analysis in European children from the IDEFICS Cohort.
Not available
S-EPMC5325300
|
biostudies-literature
Cite
Schwann Cell-Specific Ablation of Beclin 1 Impairs Myelination and Leads to Motor and Sensory Neuropathy in Mice.
Not available
S-EPMC11792035
|
biostudies-literature
Cite
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study.
Not available
S-EPMC12077285
|
biostudies-literature
Cite
A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
Not available
S-EPMC8530918
|
biostudies-literature
Cite
Auditory cortex hypoperfusion: a metabolic hallmark in Beta Thalassemia.
Not available
S-EPMC8340544
|
biostudies-literature
Cite
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment.
Not available
S-EPMC4648524
|
biostudies-literature
Cite
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.
Not available
S-EPMC12921449
|
biostudies-literature
Cite
Liquid biopsy in Oncology: Results of a Delphi consensus study endorsed by the AIOM-SIAPEC/IAP-SIBioC-SIF Italian scientific societies.
Not available
S-EPMC12803951
|
biostudies-literature
Cite
Characteristics and Outcomes of Prolonged Venoarterial Extracorporeal Membrane Oxygenation After Cardiac Surgery: The Post-Cardiotomy Extracorporeal Life Support (PELS-1) Cohort Study.
Not available
S-EPMC11392071
|
biostudies-literature
Cite
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Not available
S-EPMC7988288
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets